BioCIS , Univ. Paris-Sud, CNRS, équipe labellisée Ligue Contre le Cancer, Université Paris-Saclay , 92290 Châtenay-Malabry , France.
Vectorologie et thérapeutiques anticancéreuses, UMR 8203 CNRS , Univ. Paris-Sud, Institut Gustave Roussy , Université Paris-Saclay, Villejuif 94805 , France.
J Med Chem. 2018 Aug 9;61(15):6574-6591. doi: 10.1021/acs.jmedchem.8b00050. Epub 2018 Jul 26.
Designing multitarget drugs have raised considerable interest due to their advantages in the treatment of complex diseases such as cancer. Their design constitutes a challenge in antitumor drug discovery. The present study reports a dual inhibition of tubulin polymerization and HDAC activity. On the basis of 1,1-diarylethylenes ( isoCA-4) and belinostat, a series of hybrid molecules was successfully designed and synthesized. In particular compounds, 5f and 5h were proven to be potent inhibitors of both tubulin polymerization and HDAC8 leading to excellent antiproliferative activity.
由于在治疗癌症等复杂疾病方面具有优势,设计多靶标药物引起了相当大的兴趣。它们的设计是抗肿瘤药物发现的一个挑战。本研究报告了对微管蛋白聚合和 HDAC 活性的双重抑制。基于 1,1-二芳基乙烯(isoCA-4)和贝林司他,成功设计和合成了一系列杂合分子。特别是化合物 5f 和 5h 被证明是微管蛋白聚合和 HDAC8 的有效抑制剂,具有优异的抗增殖活性。